Analysts Set Regulus Therapeutics Inc. (NASDAQ:RGLS) Price Target at $10.80

Regulus Therapeutics Inc. (NASDAQ:RGLS) has earned a consensus recommendation of “Moderate Buy” from the six brokerages that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $10.80.

Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Regulus Therapeutics in a report on Wednesday, February 26th.

Regulus Therapeutics Trading Down 5.8 %

Shares of Regulus Therapeutics stock opened at $1.29 on Monday. The firm has a market capitalization of $84.50 million, a PE ratio of -1.21 and a beta of 1.42. Regulus Therapeutics has a 12 month low of $0.83 and a 12 month high of $3.79. The business’s 50-day moving average price is $1.30 and its 200-day moving average price is $1.47.

Insiders Place Their Bets

In other Regulus Therapeutics news, CEO Joseph P. Hagan sold 115,290 shares of the stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $1.26, for a total value of $145,265.40. Following the completion of the sale, the chief executive officer now owns 222,572 shares in the company, valued at approximately $280,440.72. This trade represents a 34.12 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Crispina Calsada sold 38,716 shares of the firm’s stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $1.26, for a total value of $48,782.16. Following the completion of the transaction, the chief financial officer now owns 50,566 shares of the company’s stock, valued at approximately $63,713.16. The trade was a 43.36 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 223,998 shares of company stock worth $282,237. 4.35% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in RGLS. Creative Planning purchased a new position in shares of Regulus Therapeutics in the 3rd quarter valued at approximately $26,000. Victory Capital Management Inc. lifted its stake in shares of Regulus Therapeutics by 10.4% in the 3rd quarter. Victory Capital Management Inc. now owns 398,866 shares of the biopharmaceutical company’s stock valued at $626,000 after purchasing an additional 37,480 shares during the period. The Manufacturers Life Insurance Company purchased a new position in shares of Regulus Therapeutics in the 3rd quarter valued at approximately $204,000. NEA Management Company LLC purchased a new position in shares of Regulus Therapeutics in the 3rd quarter valued at approximately $10,154,000. Finally, Point72 Asset Management L.P. purchased a new position in shares of Regulus Therapeutics in the 3rd quarter valued at approximately $1,403,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.